Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Alogliptin 6.25 mg QD
Total, all-cause mortality	Alogliptin 12.5 mg QD
Total, all-cause mortality	Alogliptin 25 mg QD
Total, all-cause mortality	Alogliptin 50 mg QD
Total, all-cause mortality	Voglibose 0.2 mg TID
Total, other adverse events	Alogliptin 6.25 mg QD	78	96
Total, other adverse events	Alogliptin 12.5 mg QD	81	101
Total, other adverse events	Alogliptin 25 mg QD	81	97
Total, other adverse events	Alogliptin 50 mg QD	88	97
Total, other adverse events	Voglibose 0.2 mg TID	74	83
Total, serious adverse events	Alogliptin 6.25 mg QD	2	96
Total, serious adverse events	Alogliptin 12.5 mg QD	8	101
Total, serious adverse events	Alogliptin 25 mg QD	8	97
Total, serious adverse events	Alogliptin 50 mg QD	5	97
Total, serious adverse events	Voglibose 0.2 mg TID	4	83

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01263496/event-totals